Expression of Matrix Metalloproteinase-10 in Renal Cell Carcinoma and Its Prognostic Role

European Urology

Volumn 52, Issue 3, 2007, Pages 791-797

  Miyata, Yasuyoshi ^a   Iwata, Takahisa ^a   Maruta, Sugure ^a   Kanda, Shigeru ^b   Nishikido, Masaharu ^a   Koga, Shigehiko ^a   Kanetake, Hiroshi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Angiogenesis; Invasion; MMP 10; Renal cell carcinoma; Survival

Indexed keywords

CD34 ANTIGEN; KI 67 ANTIGEN; STROMELYSIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPUTER ASSISTED RADIOGRAPHY; CORRELATION ANALYSIS; CYTOPLASM; DENSITY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 10; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 34547226659     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.12.028     Document Type: Article

References (30)

1. Uzzo R.G., Cherullo E.E., Myles J., et al. Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol 167 (2002) 2392-2396
2. Egelblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
3. Deryugina E.I., and Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25 (2006) 9-34
4. Pavlaki M., and Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of the phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22 (2003) 177-203
5. Davidson B., Goldberg I., Gotlieb W.H., et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17 (1999) 799-808
6. Herbst R.S., Yano S., Kuniyasu H., et al. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 6 (2000) 790-797
7. Lein M., Jung K., Laube C., et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 85 (2000) 801-804
8. Slaton J.W., Inoue K., Perrotte P., et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158 (2001) 735-743
9. Cho N.H., Shim H.S., Rha S.Y., et al. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 44 (2003) 560-566
10. Hagemann T., Gunawan B., Schulz M., et al. mRNA expression of matrix matalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. Eur J Cancer 37 (2001) 1839-1846
11. Sumi T., Nakatani T., Yoshida H., et al. Expression of matrix metalloproteinase-7 and 2 in human renal cell carcinoma. Oncol Rep 10 (2003) 567-570
12. Nagase H., and Woessner J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
13. Mathew R., Khanna R., kumar R., et al. Stromelysis-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Cancer Detect Prev 26 (2002) 222-228
14. Cho N.H., Hong K.P., Hong S.H., et al. MMP expression profiling in recurred stage IB lung cancer. Oncogene 23 (2004) 845-851
15. Riddick A.C.P., Shukla C.J., Pennington C.J., et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Brit J Cancer 92 (2005) 2171-2180
16. Fuhrman S.A., Lasky L.C., and Limas C.L. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Pathol 6 (1982) 655-663
17. Gill J.H., Kirwan I.G., Seargent J.M., et al. MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia 6 (2004) 777-785
18. Kerkela E., Ala-Aho R., Lohi J., et al. Differential patterns of stromelysis-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancer. Br J Cancer 84 (2001) 659-669
19. Seargent J.M., Loadman P.M., Martin S.W., et al. Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology 65 (2005) 815-820
20. Ohba K., Miyata Y., Kanda S., et al. Expression of nm23-H1 gene product in sarcomatous cancer cells of renal cell carcinoma: correlation with tumor stage and expression of matrix metalloproteinase-2, matrix metalloproteinase-9, sialyl lewis X, and c-erbB-2. Urology 65 (2005) 1029-1034
21. Roebuck M.M., Helliwell T.R., Chaudhry I.H., et al. Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. Am J Clin Pathol 123 (2005) 405-414
22. Yeatman T.J., and Nicolson G.L. Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis. Semin Surg Oncol 9 (1993) 256-263
23. Ficarra V., Martignoni G., Galfano A., et al. Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. Eur Urol 50 (2006) 786-794
24. Lopez-Beltran A., Scarpelli M., Montironi R., and Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 49 (2006) 798-805
25. MaCaulay V.M., O'Byrne K.J., Saunders M.P., et al. Phase I study of intrapleural Batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 5 (1999) 513-520
26. Jones L., Ghaneh P., Humphreys M., et al. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann N Y Acad Sci 880 (1999) 288-307
27. Gatto C., Rieppi M., Borsotti P., et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 5 (1999) 3603-3607
28. Pavlaki, and Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of the phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22 (2003) 177-203
29. Arlt M., Kopitz C., Pennington K.L., et al. Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlated with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res 62 (2002) 5543-5550
30. Hasegawa S., Koshikawa N., Momiyama N., et al. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 76 (1998) 812-816